H
Histogen
Regenerative medicine company based on naturally-produced products from newborn fibroblasts grown in a proprietary bioreactor
About Histogen
Histogen Inc. is a biotechnology company specializing in regenerative medicine, focusing on developing and commercializing products that stimulate the body's own stem cells to regenerate tissues. The company primarily serves clients in the hair growth, skincare, and orthopedic markets. Histogen operates in the biotechnology sector, leveraging its proprietary technology platform to create products that address unmet medical needs. The business model revolves around research and development, clinical trials, and subsequent commercialization of its products. Revenue is generated through product sales, licensing agreements, and partnerships with other companies in the healthcare sector. Histogen's key products include HST 001 for hair growth, HST 002 for skincare, and HST 003 for orthopedic applications. The company aims to provide innovative solutions that improve patient outcomes and quality of life.
Source: Dealroom company dataAt a glance
- Founded
- 2007
- Headquarters
- San Diego, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
US National Science Foundation
US Department of War
Series A1 investor entered at this stage
CellCeuticals Skin Care
Series B and later2 investors entered at this stage
- LVLordship Ventures
- PCPineworld Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Histogen on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Histogen on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.